Abstracts Archive - Page 445 of 2425 - ACR Meeting Abstracts

Abstract Number: 1838 • ACR Convergence 2022
Real-World Treatment Patterns Among Adult Patients with Dermatomyositis in the United States
Arielle Bensimon¹, Kristina Chen², Ahmed Noman¹, Erica Yim¹, Jason Xenakis³ and Rohit Aggarwal⁴, ¹Analysis Group, Inc., Boston, MA, ²Pfizer Inc., Cambridge, MA, ³Pfizer Inc., New York, NY, ⁴Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease characterized by muscle weakness, skin rashes, and elevated risk of associated conditions such as interstitial…
Abstract Number: 1841 • ACR Convergence 2022
To Combine or Not to Combine: Influence of Immunosuppressive Drug Combination in the Induction of Therapeutic Response in Non-infectious Uveitis
María Paula Álvarez Hernández¹, Alfredo Madrid-García², Alejandro Gómez Gómez³, Lara Borrego Sanz⁴, Rosalía Méndez Fernández⁴, Pedro Arriola Villalobos⁴, Esperanza Pato Cour⁵, David Díaz Valle⁴ and Luis Rodriguez-Rodriguez⁵, ¹Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain, Madrid, Spain, ³Hospital Infanta Sofia, Rheumatology, San Sebastián de los Reyes, Madrid, Spain, ⁴Instituto de Investigación Sanitaria San Carlos, Ophthalmology, Madrid, Spain, ⁵Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain
Background/Purpose: Non-infectious uveitides (NIUs) include a heterogeneous group of sight-threatening and incapacitating conditions. Their correct management sometimes requires the use of immunosuppressive drugs (ISDs), prescribed…
Abstract Number: 1842 • ACR Convergence 2022
Vaccination in Patients with Autoinflammatory Periodic Syndromes Under Canakinumab – Safety Data Interim Analysis of the RELIANCE Registry
Jasmin B. Kuemmerle-Deschner¹, Joerg Henes², Birgit Kortus-Goetze³, Tilmann Kallinich⁴, Prasad T. Oommen⁵, Juergen Rech⁶, Tobias Krickau⁷, Frank Weller-Heinemann⁸, Gerd Horneff⁹, Ales Janda¹⁰, Ivan Foeldvari¹¹, Catharina Schuetz¹², Frank Dressler¹³, Michael Borte¹⁴, Markus Hufnagel¹⁵, Florian Meier¹⁶, Michael Fiene¹⁷, Julia Weber-Arden¹⁸ and Norbert Blank¹⁹, ¹Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany, ²Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, ³Division of Nephrology, University of Marburg, Marburg, Germany, ⁴Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ⁵Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁶University Clinic Erlangen, Erlangen, Germany, ⁷Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany, ⁸Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, ⁹Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ¹⁰Department of Pediatrics, University Hospital Ulm, Ulm, Germany, ¹¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ¹²Pediatrics, Medizinische Fakultaet Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany, ¹³Division of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany, ¹⁴ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Sachsen, Germany, ¹⁵Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, ¹⁶Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt, Germany, ¹⁷Rheumatology Center Greifswald, Greifswald, Germany, ¹⁸Novartis Pharma GmbH, Nuernberg, Germany, ¹⁹Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
Background/Purpose: Treatment of autoinflammatory periodic syndromes with the interleukin-1β inhibitor canakinumab (CAN) has been shown to be safe and effective in clinical trials and in…
Abstract Number: 1834 • ACR Convergence 2022
Canakinumab Treatment in Familial Mediterranean Fever Patients with Colchicine Resistance: A Single-center Study
Ibrahim Durucan¹, Ali Yagiz Ayla², Helin Idil Besiroglu¹, Arif Alkan¹, Oguzhan Selvi¹, Huri Ozdogan¹ and Serdal Ugurlu², ¹Istanbul University-Cerrahpaşa Medical Faculty, Istanbul, Turkey, ²Istanbul University-Cerrahpaşa, Istanbul, Turkey
Background/Purpose: Recurrent fever and serositis are the hallmarks of Familial Mediterranean fever (FMF). Colchicine is known for yielding high success in disease control by obviating…
Abstract Number: 1836 • ACR Convergence 2022
Schizophrenia and Its Relationship with Autoimmunity: A Nationwide Analysis
Faria Sami¹, Dennis Kumi¹, Sumbul Liaqat² and Hania Sami³, ¹John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ²Rush University Medical Center, Chicago, IL, ³Shalamar Medical and Dental College, Chicago, IL
Background/Purpose: It has been hypothesized that autoimmunity may play a role in the pathophysiology of schizophrenia (SCZ). Several autoimmune disorders (AID) have also been noted…
Abstract Number: 1825 • ACR Convergence 2022
Vascular Calcifications Adjacent to the Involved Joint of Patients Diagnosed with Calcium Pyrophosphate Crystal Arthritis – a Retrospective Observational Study
Shay Brikman¹, Amir Bieber² and Reuven Mader¹, ¹Rheumatic Diseases Unit, Emek Medical Center, Afula, Israel, ²Emek Medical Center, Raanana, Israel
Background/Purpose: Prior studies have shown an association between chondrocalcinosis (CC) and vascular calcifications. In this study, we aimed to assess the presence of vascular calcifications…
Abstract Number: 1819 • ACR Convergence 2022
Calcium Pyrophosphate Deposition Disease Is Associated with an Increased Prevalence of Nephrolithiasis
Alison Fernandes¹, Yiran Jiang², Katherine Sherman³, Ikechukwu Mbonu², Rebecca Weiner² and Ann Rosenthal², ¹Medical College of Wisconsin, Oconomowoc, WI, ²Medical College of Wisconsin, Milwaukee, WI, ³Zablocki VA Medical Center, Milwaukee, WI
Background/Purpose: Calcium pyrophosphate deposition disease (CPDD) is a crystal arthropathy caused by calcium pyrophosphate (CPP) crystals. Individuals with CPDD also have increased risks for other…
Abstract Number: 1349 • ACR Convergence 2022
Priority Educational Topics to Deliver Information About Immune Checkpoint Inhibitors for Patients with Cancer and a Pre-Existing Autoimmune Disease
Maria A. Lopez-Olivo¹, Juan Ruiz², Gabrielle Duhon², Mehmet Altan³, Hussein Tawbi², Adi Diab⁴, Clifton O. Bingham III⁵, Cassandra Calabrese⁶, Natalia I. Heredia⁷, Robert J. volk² and Maria Suarez-Almazor⁸, ¹The University of Texas, MD Anderson Cancer Center, Houston, TX, ²The University of Texas MD Anderson Cancer Center, Houston, TX, ³Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, ⁴UT MD Anderson Cancer Center, Houston, TX, ⁵Johns Hopkins University, Baltimore, MD, ⁶Cleveland Clinic Foundation, Cleveland Heights, OH, ⁷The University of Texas Health Science Center at Houston, School of Public Health, Houston, TX, ⁸MD Anderson Cancer Center, Houston, TX
Background/Purpose: Immune checkpoint inhibitors (ICI) have improved cancer outcomes but can cause severe toxicity and flares in cancer patients with pre-existing autoimmune disease. The objective…
Abstract Number: 1806 • ACR Convergence 2022
Characteristics and Comorbidity Burden of Phase 3 Clinical Trial Participants Who Did and Did Not Experience Acute Gout Flares During Biweekly Pegloticase Dosing
Naomi Schlesinger¹, Lissa Padnick-Silver², Katie Obermeyer² and Brian LaMoreaux², ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Horizon Therapeutics plc, Deerfield, IL
Background/Purpose: Acute gout flare often accompanies urate-lowering therapy initiation and is the most common adverse event associated with pegloticase, a recombinant pegylated uricase that rapidly…
Abstract Number: 1357 • ACR Convergence 2022
The ANCA-Associated Vasculitis Patient-Reported Outcome (AAV-PRO) Captures Depression and Health-Related Quality of Life More Than Disease Activity and Damage
Annika Maunz¹, Joerg Henes², Joanna Robson³, Johann Jacoby⁴, Bernhard Hellmich⁵ and Christian Löffler⁶, ¹Medius Kliniken - Teaching Hospital University of Tübingen, Kirchheim-Teck, Tübingen, Germany, ²Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, ³UWE Bristol, Bristol, United Kingdom, ⁴University Hospital Tübingen, Institute for Clinical Epidemiology and Applied Biometry, Tübingen, Germany, ⁵Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, ⁶Medius Kliniken - Teaching Hospital University of Tübingen,, Kirchheim Teck, Germany
Background/Purpose: The ANCA-associated vasculitis patient-reported outcome (AAV-PRO) is a new disease-specific PRO developed to capture the impact of having AAV and dealing with its treatment…
Abstract Number: 1808 • ACR Convergence 2022
Assessing the Role of the NLRP3 Inflammasome in Driving Inflammation in Affected Joints of Patients with Inter-critical Gout
Swamy Venuturupalli¹, Ami Ben-artzi², Tasmia Amjad³, Amit Kumar⁴, Nikhil Davuluri³, Timothy Chu³, Umair Khan³, Diego Parra³, Natalie Fortune³ and Caroline Jefferies¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Ami Ben-Artzi, MD Inc., Beverly Hills, CA, ³Attune Health, Beverly Hills, CA, ⁴Attune Health, Beverly Hils, CA
Background/Purpose: Percutaneous ultrasound-guided needle synovial biopsies can now be performed at the bedside. To date, no synovial biopsy studies have been conducted in gout patients.…
Abstract Number: 1803 • ACR Convergence 2022
Neutrophil-to-lymphocyte Ratio Among Flaring and Non-flaring Uncontrolled Gout Patients Undergoing Pegloticase Therapy as Part of the Phase 3 Pivotal Trials
Michael Pillinger¹, Katie Obermeyer², Lissa Padnick-Silver² and Brian LaMoreaux², ¹NYU Grossman School of Medicine, New York, NY, ²Horizon Therapeutics plc, Deerfield, IL
Background/Purpose: Gout flares result from an innate immune response against monosodium urate crystal deposits, resulting in macrophage crystal phagocytosis and cellular activation.1 NLRP3 inflammasome activation…
Abstract Number: 1823 • ACR Convergence 2022
Unsupervised Cluster Analysis of Clinical and Ultrasound Features Reveals Unique Gout Subtypes: Results from the Egyptian College of Rheumatology (ECR)
Tamer A Gheita¹, Ahmed M Elsaman², Aly Bakhiet³, Mohamed Bakrey Mahmoud⁴, Faten Ismail⁵, Hanan El Saadany⁶, Rawhya R ElShereef⁵, Eman F Mohamed⁷, Mervat I Abd Elazeem⁸, Ayman Eid⁸, Fatma Ali⁵, Mona Hamdy⁵, Reem El Mallah⁹, Reem HA Mohammed¹, Samar Tharwat¹⁰, Rania M Gamal¹¹, Samar Fawzy¹, Soha Senara¹², Hanan M Fathi¹², Adham Aboul Fotouh¹³ and Nevin Hammam¹⁴, ¹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ²Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt, ³Higher Institute for Computer Science and Information Systems, 6th of October City, Assiut, Egypt, ⁴Higher Institute for Computer Science and Information Systems, 6th of October City, Cairo, Egypt, ⁵Rheumatology Department, Faculty of Medicine, Minia University, Minia, Egypt, ⁶Rheumatology Department, Tanta University, Gharbia, Egypt, ⁷Internal Medicine Department, Rheumatology Unit, Faculty of Medicine (Girls), Al-Azhar University, Cairo, Egypt, ⁸Rheumatology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt, ⁹Rheumatology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt, ¹⁰Internal Medicine, Rheumatology Unit, Mansoura University, Dakahlia, Egypt, Dakahlia, Egypt, ¹¹Rheumatology Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt, ¹²Rheumatology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt, ¹³Egyptian School for Musculoskeletal Ultrasonography (EgySMUS); Egyptian Society of Musculoskeletal and Neuromuscular Sonography (ESMNS), Cairo, Egypt, ¹⁴Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, PASADENA, CA
Background/Purpose: Gout comprises a heterogeneous group of disorders characterized by inflammatory arthritis associated with comorbidities leading to impaired quality of life, and an extensive burden…
Abstract Number: 1821 • ACR Convergence 2022
Colchicine and Other Gout Medications and the Risk of COVID-19 Infection, Hospitalization, and Subsequent Outcomes in People with Gout
Jasvinder singh¹, Timothy Bergquist², Vithal Madhira³ and Alfred Anzalone⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Sage Bionetworks, Seattle, WA, ³Palila Software, L.L.C., Reno, NV, ⁴University of Nebraska Medical Center, Ohama, NE
Background/Purpose: To examine whether the use of colchicine and other gout medications is associated with the risk of COVID-19 infection, hospitalization, and subsequent outcomes in…
Abstract Number: 1814 • ACR Convergence 2022
Pegloticase for Uncontrolled Gout in Patients with History of Kidney Transplant: Pharmacokinetics and Immunogenicity in the PROTECT Clinical Trial
Abdul Abdellatif¹, Yan Xin², Jason Chamberlain³, Lin Zhao², Katya Cherny³, Brad Marder⁴, John D Scandling⁵ and kenneth saag⁶, ¹Kidney Hypertension Transplant Clinic Clear Lake Specialties, Webster, TX, ²Horizon Therapeutics, Deerfield, IL, ³Horizon Therapeutics plc, Deerfield, IL, ⁴Horizon Therapeutics, Denver, CO, ⁵Stanford University School of Medicine, Division of Nephrology, Palo Alto, CA, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Immunomodulator co-therapy with pegloticase has been shown to reduce immunogenicity (anti-drug antibody [ADA] development), which markedly improves response rates with pegloticase while reducing risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].